Human single-chain antibodies that neutralize Pseudomonas aeruginosa-exotoxin A-mediated cellular apoptosis.
Sirijan SantajitWatee SeesuayKodchakorn MahasongkramNitat SookrungSumate AmpawongOnrapak ReamtongPornphan DiraphatWanpen ChaicumpaNitaya IndrawattanaPublished in: Scientific reports (2019)
Targeting bacterial virulence factors directly provides a new paradigm for the intervention and treatment of bacterial diseases. Pseudomonas aeruginosa produces a myriad of virulence factors to cause fatal diseases in humans. In this study, human single-chain antibodies (HuscFvs) that bound to P. aeruginosa exotoxin A (ETA) were generated by phage display technology using recombinant ETA, ETA-subdomains and the synthetic peptide of the ETA-catalytic site as baits for selecting ETA-bound-phages from the human-scFv phage display library. ETA-bound HuscFvs derived from three phage-transfected E. coli clones neutralized the ETA-induced mammalian cell apoptosis. Computerized simulation demonstrated that these HuscFvs used several residues in their complementarity-determining regions (CDRs) to form contact interfaces with the critical residues in ETA-catalytic domain essential for ADP-ribosylation of eukaryotic elongation factor 2, which should consequently rescue ETA-exposed-cells from apoptosis. The HuscFv-treated ETA-exposed cells also showed decremented apoptosis-related genes, i.e., cas3 and p53. The effective HuscFvs have high potential for future evaluation in animal models and clinical trials as a safe, novel remedy for the amelioration of exotoxin A-mediated pathogenesis. HuscFvs may be used either singly or in combination with the HuscFv cognates that target other P. aeruginosa virulence factors as an alternative therapeutic regime for difficult-to-treat infections.
Keyphrases
- pseudomonas aeruginosa
- biofilm formation
- cystic fibrosis
- cell cycle arrest
- endothelial cells
- escherichia coli
- clinical trial
- oxidative stress
- endoplasmic reticulum stress
- acinetobacter baumannii
- staphylococcus aureus
- cell death
- induced apoptosis
- randomized controlled trial
- induced pluripotent stem cells
- high glucose
- pluripotent stem cells
- cell proliferation
- signaling pathway
- current status
- risk assessment
- study protocol
- cancer therapy
- combination therapy
- phase ii